Unani Drug Safety Signal Reporting: A Scientific Review for Healthcare Professionals

Abstract

Unani medicine, with its extensive pharmacopeia and centuries-old therapeutic legacy, remains a popular complementary system in many parts of the world. However, the increasing use of Unani drugs necessitates vigilant safety signal reporting to ensure patient safety and maintain scientific credibility. This review critically examines the current landscape of Unani drug safety signal reporting, outlining the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic challenges, management strategies, recent advances, and guideline recommendations. Emphasis is placed on the integration of evidence-based pharmacovigilance methodologies tailored to Unani practice, exploring their clinical implications and the evolving regulatory landscape. The article targets clinicians, pharmacologists, and healthcare professionals seeking a concise yet comprehensive understanding of Unani drug safety monitoring, its practical challenges, and future directions.

Introduction

Unani medicine, rooted in Greco-Arabic principles, is widely practiced in South Asia, the Middle East, and beyond. As global interest in traditional systems grows, the safety of Unani drugs demands rigorous evaluation parallel to allopathic pharmacovigilance standards. The unique composition of Unani formulations often polyherbal, mineral, or animal-based poses specific challenges in signal detection, assessment, and reporting. Given the increasing integration of Unani therapies into mainstream healthcare, clinicians must be equipped with robust tools and knowledge to recognize, document, and communicate adverse drug reactions (ADRs) specific to this discipline. This review synthesizes current evidence and guidelines, providing a foundation for the systematic reporting and management of Unani drug safety signals in clinical practice.

Epidemiology / Disease Burden

Unani medicine is utilized by millions globally, with India alone accounting for a significant proportion of practitioners and patients. Despite its widespread use, the precise epidemiological burden of Unani drug-related adverse events remains underreported due to fragmented surveillance systems and cultural perceptions of safety associated with traditional remedies. Published studies indicate sporadic case reports of hepatotoxicity, nephrotoxicity, and hypersensitivity reactions, often linked to polyherbal preparations or adulterated products. The true incidence of ADRs is likely underestimated, as community-based surveys suggest a high prevalence of self-medication and non-disclosure of traditional drug use to healthcare providers. Strengthening epidemiological surveillance through dedicated Unani pharmacovigilance networks is essential for accurate disease burden estimation and effective signal detection.

Pathophysiology

The pathophysiological basis of Unani drug-induced adverse events is multifactorial. Many Unani formulations contain multiple active constituents, which may interact synergistically or antagonistically, altering pharmacokinetics and pharmacodynamics. Heavy metals (e.g., mercury, arsenic), when present even in trace amounts, can exert cumulative toxicity. Immunological mechanisms may underlie hypersensitivity reactions, while metabolic idiosyncrasies contribute to organ-specific toxicity such as hepatocellular injury or renal impairment. The lack of standardized extraction and purification processes further compounds the risk, as does the presence of contaminants or adulterants. Detailed mechanistic studies focusing on individual and composite ingredients are critical for elucidating ADR pathways and informing risk mitigation strategies.

Risk Factors

Risk factors for Unani drug-related ADRs include patient-specific variables (age, comorbidities, hepatic/renal function), polypharmacy, genetic predisposition, and the use of high-risk formulations containing heavy metals or potent botanicals. Inadequate dosing, poor-quality control, and self-medication without professional guidance significantly increase susceptibility to adverse outcomes. Special populations, such as pregnant women, children, and the elderly, are particularly vulnerable. Additionally, the concurrent use of Unani and allopathic medicines can result in unforeseen drug-drug interactions, emphasizing the need for comprehensive medication reconciliation and patient education in clinical practice.

Clinical Features

The clinical spectrum of Unani drug-induced adverse events ranges from mild gastrointestinal disturbances to severe organ toxicity, dermatological reactions, and life-threatening hypersensitivity syndromes. Hepatotoxicity presents as jaundice, right upper quadrant pain, and abnormal liver function tests, while nephrotoxicity may manifest as acute kidney injury or chronic renal dysfunction. Dermatological ADRs include urticaria, exanthematous eruptions, and, rarely, Stevens-Johnson syndrome. Neurological and hematological manifestations have also been described, albeit less frequently. Prompt recognition of these clinical features is pivotal for early diagnosis and intervention.

Diagnosis

Diagnosis of Unani drug-induced ADRs requires a high index of suspicion, detailed drug history (including all traditional and complementary medicines), and exclusion of alternative etiologies. Laboratory investigations tailored to suspected organ involvement (e.g., liver enzymes, renal function, hematology panels) are essential. Causality assessment tools, such as the WHO-UMC criteria or Naranjo scale, can be adapted for Unani pharmacovigilance, although validation in this context is ongoing. Advanced diagnostic modalities, including immunological assays or biomarkers of organ damage, may aid in complex cases. Documentation and reporting to national pharmacovigilance centers are mandatory for signal generation and regulatory action.

Treatment & Management

Management of Unani drug-induced ADRs hinges on immediate withdrawal of the suspected agent, supportive care, and targeted therapy based on the affected organ system. For severe reactions, hospitalization and multidisciplinary intervention may be required. Use of specific antidotes is generally limited, underscoring the importance of preventive strategies and early detection. Patient education on potential adverse effects, the importance of reporting symptoms, and adherence to prescribed doses form the cornerstone of safe Unani drug use. Clinician engagement with regulatory authorities and pharmacovigilance programs enhances collective learning and patient safety.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of Unani-specific pharmacovigilance guidelines, integration of digital reporting platforms, and increased collaboration between traditional and modern medicine stakeholders. Emerging approaches involve artificial intelligence-driven signal detection, electronic health records integration, and community-based surveillance models. Analytical advancements, such as high-resolution mass spectrometry for ingredient profiling and biomarker discovery, are improving the specificity of ADR attribution. Educational initiatives targeting Unani practitioners and patients are fostering a culture of proactive safety monitoring, crucial for early identification of signals and prevention of serious outcomes.

Guideline Recommendations

National and international agencies including the Central Council for Research in Unani Medicine (CCRUM), Ministry of AYUSH, and WHO advocate for systematic safety signal reporting in Unani practice. Key recommendations include mandatory documentation of all suspected ADRs, use of standardized causality assessment tools, periodic training for practitioners, and public awareness campaigns. Integration of Unani pharmacovigilance with national drug safety databases is strongly encouraged. Implementation of Good Manufacturing Practices (GMP) and quality assurance protocols is essential for minimizing risks associated with adulteration and contamination. The guidelines emphasize continuous data collection, transparent communication, and feedback mechanisms to enhance pharmacovigilance efficacy.

Conclusion

As Unani medicine continues to play a significant role in global healthcare, robust drug safety signal reporting becomes indispensable for safeguarding public health. Clinicians and healthcare professionals must remain vigilant, leveraging evidence-based tools and guidelines to detect, assess, and manage Unani drug-induced adverse events. Ongoing research, regulatory oversight, and education will pave the way for safer therapeutic outcomes and sustained credibility of Unani medicine in the modern era.